Rosiglitazone doubles heart failure risk
By Lilian Anekwe
Rosiglitazone does not increase the risk of death from cardiovascular disease, but does double the risk of heart failure, a new analysis shows.
The findings of the RECORD study found 61 patients given rosiglitazone as a second-line drug suffered heart failure causing hospitalisation or death, compared with 29 people on a combination of metformin and sulfonylurea. There were no significant differences in any other cardiovascular endpoint.
Treatment with rosiglitazone also increased the risk of fracture by more than half, by 57%, with the increased risk of fractures much higher in women – at 82% – then the 23% seen in men.
Lead researcher Dr Philip Home, chair of the RECORD steering committee and a professor of diabetes medicine at Newcastle university said: 'Rosiglitazone carries no increased risk of overall cardiovascular death or hospitalisation compared to most commonly used diabetes medicines.'
The study was published in The Lancet and presented at the American Diabetes Association conference in New Orleans last week.